Increased K2 intake cuts prostate cancer risk

4 May 2008

An increased intake of vitamin K2 may reduce the risk of prostate cancer by 35%, according to data from 11,319 men taking part in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition.

The findings, which are published in the April issue of the American Journal of Clinical Nutrition, found that dietary intake of K2 was linked to an inverse association with prostate cancer, while vitamin K1 consumption did not offer any prostate benefits, report the researchers from the German Cancer Research Center in Heidelberg.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Vaxcyte

A US clinical-stage vaccine company in San Carlos, California, whose 31-valent pneumococcal conjugate vaccine VAX-31 met every primary endpoint of its pivotal adult Phase III trial in October 2026, with a BLA planned for the first half of 2028 and $2.51 billion of cash to get there.

| Headless Content Management with Blaze